A Synthetic Microbial Therapy Rewires Antitumor Immunity Across Multiple Cancer Types
Das, J. K.; Qin, Q.-M.; Singh, S.; James Thomas, C.; Gupta, S.; Chatterjee, A.; Sunnagatta Nagaraja, S.; Guo, F.; Delgado, K.; Kumar, A.; Ryu, E.; Flannagan, B.; Agca, C.; Agca, Y.; Powell, N.; Barry, E.; Kahl-Mcdonagh, M. M.; Chaki, S. P.; Mendes Ribeiro Correa, A.; Niyakan, S.; Han, S.; Cai, J.; Qian, X.; Kobayashi, K. S.; Han, A.; Jayaraman, A.; Ficht, T. A.; Adams, L. G.; Alaniz, R.; Yee, C.; Song, J.; de Figueiredo, P.
Show abstract
Microbial immunotherapies show promise against cancer, yet broad efficacy and mechanistic insight remain elusive. Here, we introduce SPIKE 1.0 (S1.0), a metabolically engineered bacterium that converts tryptophan into immunomodulatory hydroxyindoles via tryptophan monooxygenase to remodel the tumor microenvironment (TME). A single systemic dose of S1.0 elicited potent, durable antitumor responses across multiple murine models, including humanized mice, with minimal toxicity. S1.0 enhanced inflammatory signaling, activated innate and adaptive immunity, and promoted T cell persistence, memory, and resistance to exhaustion. It outperformed checkpoint inhibitors and synergized with chemotherapy. Multi-omics profiling revealed that S1.0 rewired amino acid metabolism in tumor-infiltrating immune cells and disrupted immunosuppressive networks. These results establish S1.0 as a scalable, cost-effective microbial immunotherapy with broad translational potential for solid tumors.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 97%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 97%
- A Paradoxical Tumor Antigen Specific Response in the Liver 96%
Similar papers in this journal
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 97%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy 95%
Similar papers in this journal
- Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner 96%
- Lung cancer-intrinsic SOX2 expression mediates resistance to checkpoint blockade therapy by inducing Treg-dependent CD8+ T cell exclusion 96%
- Combining an alarmin HMGN1 peptide with PD-L1 blockade facilitates stem-like CD8+ T cell expansion and results in robust antitumor effects 96%
Similar papers in this journal
Similar papers in this journal
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 96%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 96%
- Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastoma 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.